vs
Side-by-side financial comparison of Charles River Laboratories (CRL) and MILLERKNOLL, INC. (MLKN). Click either name above to swap in a different company.
Charles River Laboratories is the larger business by last-quarter revenue ($994.2M vs $955.2M, roughly 1.0× MILLERKNOLL, INC.). MILLERKNOLL, INC. runs the higher net margin — 2.5% vs -27.8%, a 30.3% gap on every dollar of revenue. On growth, Charles River Laboratories posted the faster year-over-year revenue change (-0.8% vs -1.6%). Charles River Laboratories produced more free cash flow last quarter ($58.6M vs $34.0M).
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices.
MillerKnoll, Incorporated, doing business as Herman Miller, is an American company that produces office furniture, equipment, and home furnishings. Its best known designs include the Aeron chair, Noguchi table, Marshmallow sofa, Mirra chair, and Eames Lounge Chair. Herman Miller is also credited with the 1968 invention of the office cubicle under then–director of research Robert Propst.
CRL vs MLKN — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $994.2M | $955.2M |
| Net Profit | $-276.6M | $24.2M |
| Gross Margin | — | 39.0% |
| Operating Margin | -28.5% | 5.1% |
| Net Margin | -27.8% | 2.5% |
| Revenue YoY | -0.8% | -1.6% |
| Net Profit YoY | -28.9% | -29.0% |
| EPS (diluted) | $-5.57 | $0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $994.2M | $955.2M | ||
| Q3 25 | $1.0B | $955.7M | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $984.2M | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $1.0B | — | ||
| Q1 24 | $1.0B | — |
| Q4 25 | $-276.6M | $24.2M | ||
| Q3 25 | $54.4M | $20.2M | ||
| Q2 25 | $52.3M | — | ||
| Q1 25 | $25.5M | — | ||
| Q4 24 | $-214.5M | — | ||
| Q3 24 | $69.7M | — | ||
| Q2 24 | $94.1M | — | ||
| Q1 24 | $73.0M | — |
| Q4 25 | — | 39.0% | ||
| Q3 25 | — | 38.5% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 34.6% | — | ||
| Q2 24 | 34.5% | — | ||
| Q1 24 | 34.1% | — |
| Q4 25 | -28.5% | 5.1% | ||
| Q3 25 | 13.3% | 5.6% | ||
| Q2 25 | 9.7% | — | ||
| Q1 25 | 7.6% | — | ||
| Q4 24 | -16.7% | — | ||
| Q3 24 | 11.6% | — | ||
| Q2 24 | 14.8% | — | ||
| Q1 24 | 12.5% | — |
| Q4 25 | -27.8% | 2.5% | ||
| Q3 25 | 5.4% | 2.1% | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 2.6% | — | ||
| Q4 24 | -21.4% | — | ||
| Q3 24 | 6.9% | — | ||
| Q2 24 | 9.2% | — | ||
| Q1 24 | 7.2% | — |
| Q4 25 | $-5.57 | $0.35 | ||
| Q3 25 | $1.10 | $0.29 | ||
| Q2 25 | $1.06 | — | ||
| Q1 25 | $0.50 | — | ||
| Q4 24 | $-4.17 | — | ||
| Q3 24 | $1.33 | — | ||
| Q2 24 | $1.74 | — | ||
| Q1 24 | $1.30 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $213.8M | $180.4M |
| Total DebtLower is stronger | $2.1B | $1.3B |
| Stockholders' EquityBook value | $3.2B | $1.3B |
| Total Assets | $7.1B | $3.9B |
| Debt / EquityLower = less leverage | 0.68× | 1.02× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $213.8M | $180.4M | ||
| Q3 25 | $207.1M | $167.2M | ||
| Q2 25 | $182.8M | — | ||
| Q1 25 | $229.4M | — | ||
| Q4 24 | $194.6M | — | ||
| Q3 24 | $210.2M | — | ||
| Q2 24 | $179.2M | — | ||
| Q1 24 | $327.0M | — |
| Q4 25 | $2.1B | $1.3B | ||
| Q3 25 | $2.2B | $1.3B | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.7B | — |
| Q4 25 | $3.2B | $1.3B | ||
| Q3 25 | $3.4B | $1.3B | ||
| Q2 25 | $3.4B | — | ||
| Q1 25 | $3.2B | — | ||
| Q4 24 | $3.5B | — | ||
| Q3 24 | $3.8B | — | ||
| Q2 24 | $3.7B | — | ||
| Q1 24 | $3.6B | — |
| Q4 25 | $7.1B | $3.9B | ||
| Q3 25 | $7.5B | $3.9B | ||
| Q2 25 | $7.6B | — | ||
| Q1 25 | $7.6B | — | ||
| Q4 24 | $7.5B | — | ||
| Q3 24 | $8.0B | — | ||
| Q2 24 | $7.9B | — | ||
| Q1 24 | $8.2B | — |
| Q4 25 | 0.68× | 1.02× | ||
| Q3 25 | 0.64× | 1.02× | ||
| Q2 25 | 0.70× | — | ||
| Q1 25 | 0.79× | — | ||
| Q4 24 | 0.65× | — | ||
| Q3 24 | 0.62× | — | ||
| Q2 24 | 0.65× | — | ||
| Q1 24 | 0.73× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $147.5M | $64.6M |
| Free Cash FlowOCF − Capex | $58.6M | $34.0M |
| FCF MarginFCF / Revenue | 5.9% | 3.6% |
| Capex IntensityCapex / Revenue | 8.9% | 3.2% |
| Cash ConversionOCF / Net Profit | — | 2.67× |
| TTM Free Cash FlowTrailing 4 quarters | $518.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $147.5M | $64.6M | ||
| Q3 25 | $213.8M | $9.4M | ||
| Q2 25 | $204.6M | — | ||
| Q1 25 | $171.7M | — | ||
| Q4 24 | $159.4M | — | ||
| Q3 24 | $251.8M | — | ||
| Q2 24 | $193.5M | — | ||
| Q1 24 | $129.9M | — |
| Q4 25 | $58.6M | $34.0M | ||
| Q3 25 | $178.2M | $-21.3M | ||
| Q2 25 | $169.3M | — | ||
| Q1 25 | $112.4M | — | ||
| Q4 24 | $83.7M | — | ||
| Q3 24 | $213.1M | — | ||
| Q2 24 | $154.0M | — | ||
| Q1 24 | $50.7M | — |
| Q4 25 | 5.9% | 3.6% | ||
| Q3 25 | 17.7% | -2.2% | ||
| Q2 25 | 16.4% | — | ||
| Q1 25 | 11.4% | — | ||
| Q4 24 | 8.4% | — | ||
| Q3 24 | 21.1% | — | ||
| Q2 24 | 15.0% | — | ||
| Q1 24 | 5.0% | — |
| Q4 25 | 8.9% | 3.2% | ||
| Q3 25 | 3.5% | 3.2% | ||
| Q2 25 | 3.4% | — | ||
| Q1 25 | 6.0% | — | ||
| Q4 24 | 7.5% | — | ||
| Q3 24 | 3.8% | — | ||
| Q2 24 | 3.8% | — | ||
| Q1 24 | 7.8% | — |
| Q4 25 | — | 2.67× | ||
| Q3 25 | 3.93× | 0.47× | ||
| Q2 25 | 3.91× | — | ||
| Q1 25 | 6.74× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.61× | — | ||
| Q2 24 | 2.06× | — | ||
| Q1 24 | 1.78× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRL
| Discovery And Safety Assessment Segment | $591.6M | 60% |
| Manufacturing Support Segment | $196.4M | 20% |
| Transferred At Point In Time | $108.0M | 11% |
| Transferred Over Time | $98.3M | 10% |
MLKN
| Workplace | $309.9M | 32% |
| Global Retail Segment | $275.8M | 29% |
| International Contract Segment | $170.9M | 18% |
| Performance Seating | $101.1M | 11% |
| Lifestyle | $52.9M | 6% |
| Other Products | $44.6M | 5% |
